Schizophrenia

Schizophrenia is characterized by three symptom domains and affects ~1% of global population. First and mostly known are the positive symptoms like hallucinations and delusions, secondly are negative symptoms like reduced emotion and lack of motivation and the third symptom domain is cognitive symptoms like a poor memory or disorganized thinking. While there are already many drugs for treating positive symptoms, there is a significant unmet medical need for effective treatments for negative and cognitive symptoms.

The global $1 trillion mental health problem needs more funding

The global $1 trillion mental health problem needs more funding

Nearly one billion people around the world live with a mental health condition, yet an estimated 70% don’t have access to the help they need.

Schizophrenia: beyond the stigma

The condition affects about one in 300 people worldwide. Boehringer Ingelheim is committed to helping people with schizophrenia receive the understanding, support and medical care they deserve.

Improving the current state of schizophrenia care

More than 24 million people worldwide are living with schizophrenia. Despite its global prevalence, schizophrenia is an often misunderstood, serious mental health condition. At Boehringer Ingelheim, we’ve made a long-term, generational commitment to transform the mental health landscape. 

Stable isnt

This website is an information resource about schizophrenia and its symptom domains.